Abstract
AbstractAlzheimer’s disease (AD) is one of the most prevalent neurodegenerative illnesses, and yet, no workable treatments have been discovered to prevent or reverse AD. Curcumin (CUR), the major polyphenolic compound of turmeric (Curcuma longa) rhizomes, and Ginkgo biloba extract (GBE) are natural substances derived from conventional Chinese herbs that have long been shown to provide therapeutic advantages for AD. The uptake of curcumin into the brain is severely restricted by its low ability to cross the blood–brain barrier (BBB). Meanwhile, GBE has been shown to improve BBB permeability. The present study evaluated the neuroprotective effects and pharmacokinetic profile of curcumin and GBE combination to find out whether GBE can enhance curcumin’s beneficial effects in AD by raising its brain concentration. Results revealed that CUR + GBE achieved significantly higher levels of curcumin in the brain and plasma after 30 min and 1 h of oral administration, compared to curcumin alone, and this was confirmed by reversed phase high-performance liquid chromatography (RP-HPLC). The effect of combined oral treatment, for 28 successive days, on cognitive function and other AD-like alterations was studied in scopolamine-heavy metal mixtures (SCO + HMM) AD model in rats. The combination reversed at least, partially on the learning and memory impairment induced by SCO + HMM. This was associated with a more pronounced inhibitory effect on acetylcholinesterase (AChE), caspase-3, hippocampal amyloid beta (Aβ1-42), and phosphorylated tau protein (p-tau) count, and pro-inflammatory cytokines tumor necrosis factor-alpha (TNF-α) and interleukine-1beta (IL-1β), as compared to the curcumin alone-treated group. Additionally, the combined treatment significantly decreased lipid peroxidation (MDA) and increased levels of reduced glutathione (GSH), when compared with the curcumin alone. These findings support the concept that the combination strategy might be an alternative therapy in the management/prevention of neurological disorders. This study sheds light on a new approach for exploring new phyto-therapies for AD and emphasizes that more research should focus on the synergic effects of herbal drugs in future.Graphical abstract
Funder
Science and Technology Development Fund
Assiut University
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Immunology
Reference68 articles.
1. Abbas S, Latif M, Shafie N, Ghazali M, Abidin N, Mustafa M, Kormin F (2021) A review of antioxidant and anti-acetylcholinesterase activities of Centella asiatica (L.) Urb. for the treatment of Alzheimer’s disease. Food Res 5:1–17
2. Abdelmeguid NE, Khalil MI, Elhabet R, Sultan AS, Salam SA (2021) Combination of docosahexaenoic acid and ginko biloba extract improves cognitive function and hippocampal tissue damages in a mouse model of Alzheimer’s disease. J Chem Neuroanat 116:101995
3. Akinyemi AJ, Oboh G, Oyeleye SI, Ogunsuyi O (2017) Anti-amnestic effect of curcumin in combination with donepezil, an anticholinesterase drug: involvement of cholinergic system. Neurotox Res 31:560–569
4. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB (2007) Bioavailability of curcumin: problems and promises. Mol Pharm 4:807–818
5. Antona ME, González PM, Ramos C, Cabrera J, Olano C, Morales C, Zago V, Steimetz T, Puntarulo S, Friedman SM (2021) Curcumin exerts a protective effect against obesity and liver injury induced by an atherogenic diet. Funct Foods Health Dis 11:673–689
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献